Premium
Intra‐operative cisplatin for the treatment of canine extremity soft tissue sarcomas
Author(s) -
Havlicek M.,
Straw R. S.,
Langova V.,
Dernell W. S.
Publication year - 2009
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2008.00182.x
Subject(s) - cisplatin , medicine , soft tissue , chemotherapy , surgery , implant , metastasis , cancer
Nineteen dogs with histologically confirmed soft tissue sarcomas of the extremities were treated with a combination of marginal surgery and intra‐operative chemotherapy in the form of cisplatin in a biodegradable implant delivery system (Atrigel ® ; Atrix Laboratories, Fort Collins, Co, USA). None of the dogs had evidence of metastasis at time of treatment. The median dose of cisplatin was 52.1 mg/m 2 (mean 55.4 mg/m 2 , range 18.5–108.6 mg/m 2 ). Wound complications were noted in 16 dogs (84.2%). Median follow‐up time was 874 days (mean 777 days, range 125–1463 days). Nine dogs (47.3%) were alive at the time of analysis. Local recurrence occurred in three dogs (16.6%). The time to recurrence was 214, 264 and 874 days.